MINI FUTURE SHORT - ASTRAZENECA | Market Closed - Euronext Paris 10:00:03 31/05/2024 pm IST | ||
| 3.26 EUR | -5.78% |
|
| Current month | -4.44% | ||
| 1 month | -4.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 3.23 | -6.65% |
| 30/24/30 | 3.46 | -2.26% |
| 29/24/29 | 3.54 | +1.14% |
| 28/24/28 | 3.5 | +14.38% |
| 24/24/24 | 3.06 | +6.25% |
Real-time Euronext Paris
Last update May 31, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| M57NB | |
| ISIN | NLBNPNL2R329 |
| Date issued | 26/04/2024 |
| Strike | 14,894 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.56 € |
|---|---|
| Lowest since issue | 2.84 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- M57NB Certificat
